-
1.发明授权Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies 失效调节，抑制或调节结缔组织生长因子（CTGF）的活性和/或表达的作为降低眼内压和治疗青光眼性视网膜病变/视神经病变的独特手段的药剂公开(公告)号：US07351407B2
公开(公告)日：2008-04-01
申请号：US10510585
申请日：2003-04-18
IPC分类号： A61K31/74
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
2.发明申请Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteins 审中-公开使用化学伴侣来治疗由错误折叠或错误处理的蛋白质引起的青光眼公开(公告)号：US20120101160A1
公开(公告)日：2012-04-26
申请号：US11302839
申请日：2005-12-14
申请人： Allan Shepard , Nasreen Jacobson , Abbot F. Clark
发明人： Allan Shepard , Nasreen Jacobson , Abbot F. Clark
IPC分类号： A61K31/192 , A61P27/06 , A61K31/131 , A61K31/16 , A61K31/205 , A61K31/10
CPC分类号： A61K31/10 , A61K31/14 , A61K31/16 , A61K31/197 , A61K31/205
摘要： The present invention provides methods for treating glaucoma by administering compounds capable of stabilizing misprocessed or misfolded proteins that are responsible for the condition.
摘要翻译： 本发明提供了通过施用能够稳定负责该病症的错误加工或错误折叠的蛋白质的化合物来治疗青光眼的方法。
-
3.发明申请AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES 审中-公开代理，禁止或调节连接性组织生长因子（CTGF）的活动和/或表达，作为双重下降的压力和治疗玻璃体积反射/视神经病变的独特手段公开(公告)号：US20110092523A1
公开(公告)日：2011-04-21
申请号：US12970662
申请日：2010-12-16
IPC分类号： A61K31/52 , A61K31/4439 , A61P27/02
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
4.发明申请AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES 审中-公开代理，禁止或调节连接性组织生长因子（CTGF）的活动和/或表达，作为双重下降的压力和治疗玻璃体积反射/视神经病变的独特手段公开(公告)号：US20080176964A1
公开(公告)日：2008-07-24
申请号：US12024821
申请日：2008-02-01
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
5.发明申请Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies 失效调节，抑制或调节结缔组织生长因子（ctgf）的活性和/或表达的作为降低眼内压和治疗青光眼性视网膜病变/视神经病的独特手段的药剂公开(公告)号：US20050234075A1
公开(公告)日：2005-10-20
申请号：US10510585
申请日：2003-04-18
申请人： Debra Fleenor , Allan Shepard , Nasreen Jacobson , Iok-Hou Pang , Abbot Clark
发明人： Debra Fleenor , Allan Shepard , Nasreen Jacobson , Iok-Hou Pang , Abbot Clark
IPC分类号： A61F9/007 , A61K31/00 , A61K31/202 , A61K31/404 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/519 , A61K31/52 , A61K45/00 , A61P27/02 , A61P27/06 , C12N9/99
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
公开(公告)号：US20060020001A1
公开(公告)日：2006-01-26
申请号：US10537052
申请日：2003-12-19
申请人： Allan Shepard , Abbot Clark , Nasreen Jacobson
发明人： Allan Shepard , Abbot Clark , Nasreen Jacobson
IPC分类号： A61K31/426
CPC分类号： A61K31/426 , A61K31/165
摘要： Compositions containing inhibitors of cathepsin K (CTSK) expression and/or activity are provided. Methods for the treatment of glaucoma using the compositions of the invention are further provided.
摘要翻译： 提供含有组织蛋白酶K（CTSK）表达和/或活性抑制剂的组合物。 进一步提供使用本发明组合物治疗青光眼的方法。
-
7.发明申请Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders 审中-公开使用通过TrkA / p75NTR受体复合物抑制结缔组织生长因子（CTGF）结合和信号传导的药物，用于预防和治疗CTGF介导的眼部疾病公开(公告)号：US20060275797A1
公开(公告)日：2006-12-07
申请号：US11384638
申请日：2006-03-20
申请人： Allan Shepard , Nasreen Jacobson , Abbot Clark
发明人： Allan Shepard , Nasreen Jacobson , Abbot Clark
CPC分类号： A61K31/553 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N2500/00
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one agent that inhibits binding and/or signaling of connective tissue growth factor (CTGF) via the TrkA/p75NTR receptor complex.
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种通过TrkA / p75抑制结缔组织生长因子（CTGF）的结合和/或信号传导的药物来降低眼内压并向有需要的患者提供神经保护作用的方法。 NTR 受体复合物。
-
8.发明申请Short form c-Maf transcription factor antagonists for treatment of glaucoma 审中-公开用于治疗青光眼的短型c-Maf转录因子拮抗剂公开(公告)号：US20050159432A1
公开(公告)日：2005-07-21
申请号：US11018283
申请日：2004-12-21
申请人： Allan Shepard , Nasreen Jacobson , Abbot Clark
发明人： Allan Shepard , Nasreen Jacobson , Abbot Clark
IPC分类号： A61K31/00 , A61K31/52 , A61K31/522
摘要： The short form version of c-Maf transcription factor is up-regulated in steroid-treated and transforming growth factor beta2-treated trabecular meshwork cells, and is present at elevated levels in glaucomatous versus normal trabecular meshwork cells and in glaucomatous versus normal optic nerve head tissue. Expression of short form c-Maf transcription factor under these conditions indicates a causal or effector role for the factor in primary open-angle and steroid-induced glaucoma pathogenesis. Antagonism of short form c-Maf transcription factor expression and/or activity in the trabecular meshwork or other ocular tissue is provided for inhibiting or alleviating glaucoma pathogenesis. Antagonists include cyclin-dependent kinase 2 inhibitors.
摘要翻译： c-Maf转录因子的短版本在类固醇治疗和转化生长因子β2处理的小梁细胞中上调，并且在青光眼与正常小梁网细胞和青光眼相对于正常视神经头的升高水平存在 组织。 在这些条件下，短型c-Maf转录因子的表达表明该因子在原发性开放角和类固醇诱发的青光眼发病机制中的因果或效应器作用。 提供短小型c-Maf转录因子表达和/或小梁网或其他眼组织中的活性的拮抗作用，用于抑制或减轻青光眼发病。 拮抗剂包括细胞周期蛋白依赖性激酶2抑制剂。
-
9.发明申请PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA 审中-公开用于高血压控制和GLAUCOMA治疗的PRENYLTRANSFERASE抑制剂公开(公告)号：US20070232675A1
公开(公告)日：2007-10-04
申请号：US11692316
申请日：2007-03-28
申请人： Allan Shepard , Debra Fleenor
发明人： Allan Shepard , Debra Fleenor
IPC分类号： A61K31/4172 , A61K31/195 , A61K31/557 , A61K31/24
CPC分类号： A61K31/166 , A61K31/195 , A61K31/24 , A61K31/417 , A61K31/4172 , A61K31/4178 , A61K31/4709 , A61K31/557
摘要： The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor.
摘要翻译： 本发明在一个实施方案中涉及治疗青光眼或升高的眼内压的方法，其包括施用药学有效量的包含至少一种异戊烯基转移酶抑制剂的组合物。 在另一个实施方案中，本发明涉及用于治疗眼内压升高和青光眼的组合物，其包含药学有效量的异戊烯基转移酶抑制剂。
-
10.发明申请C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H 审中-公开用于预防和治疗患有年龄相关性黄斑变性的C3-转化酶抑制剂在患有风险变异的补体因子H公开(公告)号：US20070149616A1
公开(公告)日：2007-06-28
申请号：US11614595
申请日：2006-12-21
申请人： Abbot Clark , Allan Shepard
发明人： Abbot Clark , Allan Shepard
IPC分类号： A61K31/235 , C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/215 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.
摘要翻译： 本发明提供了通过鉴定补体H基因中存在Y402H多态性或其它风险变体的方法来鉴定患有发展AMD风险的患者的方法。 本发明进一步提供了治疗患有AMD的患者或由于在补体H基因中具有Y402H多态性或其他风险变异体而发展为AMD的风险的患者的方法。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.021 秒)